Free Trial

Elevance Health (ELV) Stock Forecast & Price Target

$510.82
+8.40 (+1.67%)
(As of 01:49 PM ET)

Elevance Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 15 Wall Street analysts who have issued ratings for Elevance Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 1 has given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ELV.

Consensus Price Target

$604.29
18.30% Upside
High Forecast$649.00
Average Forecast$604.29
Low Forecast$530.00

According to the 15 analysts' twelve-month price targets for Elevance Health, the average price target is $604.29. The highest price target for ELV is $649.00, while the lowest price target for ELV is $530.00. The average price target represents a forecasted upside of 18.30% from the current price of $510.82.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$604.29$611.36$587.42$568.93
Forecasted Upside18.30% Upside16.68% Upside15.85% Upside20.52% Upside
Get Elevance Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ELV and its competitors with MarketBeat's FREE daily newsletter.

ELV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ELV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Elevance Health Stock vs. The Competition

TypeElevance HealthMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside20.28% Upside2,973.09% Upside9.26% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00+19.09%
7/22/2024Wells Fargo & Company
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$600.00 ➝ $593.00+18.60%
7/19/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$624.00 ➝ $589.00+16.60%
7/18/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$621.00 ➝ $611.00+21.70%
7/18/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$575.00 ➝ $585.00+16.17%
7/18/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$646.00 ➝ $530.00+1.89%
7/15/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$600.00 ➝ $620.00+14.90%
6/24/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$643.00+20.32%
6/11/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$615.00 ➝ $615.00+14.69%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$628.00 ➝ $631.00+24.00%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$649.00+28.38%
4/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$575.00 ➝ $585.00+9.77%
4/19/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$585.00 ➝ $605.00+13.75%
4/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$602.00 ➝ $604.00+15.01%
7/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
4/27/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade
4/21/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$565.00 ➝ $550.00+20.90%
4/20/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$571.00 ➝ $575.00+25.73%
1/26/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$580.00+17.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:14 PM ET.

ELV Forecast - Frequently Asked Questions

What is Elevance Health's forecast for 2024?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevance Health is $604.29, with a high forecast of $649.00 and a low forecast of $530.00.

Should I buy or sell Elevance Health stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevance Health in the last twelve months. There is currently 1 hold rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELV shares.

Does Elevance Health's stock price have much upside?

According to analysts, Elevance Health's stock has a predicted upside of 16.70% based on their 12-month stock forecasts.

Has Elevance Health been upgraded by Wall Street analysts recently?

Over the previous 90 days, Elevance Health's stock had 1 upgrade by analysts.

What analysts cover Elevance Health?
Do Wall Street analysts like Elevance Health more than its competitors?

Analysts like Elevance Health more than other "medical" companies. The consensus rating for Elevance Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ELV compares to other companies.


This page (NYSE:ELV) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners